HUMA (Humacyte) Buildings And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Humacyte Buildings And Improvements?

Humacyte Buildings And Improvements Historical Data

The historical data trend for Humacyte's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Buildings And Improvements Chart

Humacyte Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Humacyte Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial														-	-	-	-	-

Humacyte Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Humacyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

Executives

William John Scheessele	officer: Chief Commercial Officer	620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Dale A. Sander	officer: CFO & CCDO	11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
Shamik J Parikh	officer: Chief Medical Officer	1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Charles Bruce Green	director	3185 SCENIC DRIVE, NAPA CA 94558
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Brady W Dougan	director, 10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Laura E Niklason	director, 10 percent owner, officer: President, CEO and Director	35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard	officer: Chief Operating Officer	820 BROWNWICH STREET, WAKE FOREST NC 27587
Max N. Wallace	director	210 WEST TRYON STREET, HILLSBOROUGH NC 27278
Gordon M Binder	director	225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Ayabudge Llc	10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Yang Cao	officer: Chief Regulatory Officer	12 DOGLEG LANE, LAWRENCE NJ 08648
Diane Seimetz	director	JUTASTRASSE, MUNICH 2M 80636
Rajiv Shukla	director	EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411